Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.94
BMY's Cash to Debt is ranked higher than
68% of the 926 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. BMY: 0.94 )
BMY' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 0.94

Equity to Asset 0.45
BMY's Equity to Asset is ranked higher than
57% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. BMY: 0.45 )
BMY' s 10-Year Equity to Asset Range
Min: 0.33   Max: 0.55
Current: 0.45

0.33
0.55
Interest Coverage 15.56
BMY's Interest Coverage is ranked higher than
60% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 160.63 vs. BMY: 15.56 )
BMY' s 10-Year Interest Coverage Range
Min: 4.67   Max: 50.72
Current: 15.56

4.67
50.72
F-Score: 5
Z-Score: 5.78
M-Score: -2.89
WACC vs ROIC
8.75%
10.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 11.29
BMY's Operating margin (%) is ranked higher than
86% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.10 vs. BMY: 11.29 )
BMY' s 10-Year Operating margin (%) Range
Min: 10.45   Max: 31.29
Current: 11.29

10.45
31.29
Net-margin (%) 12.62
BMY's Net-margin (%) is ranked higher than
85% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.05 vs. BMY: 12.62 )
BMY' s 10-Year Net-margin (%) Range
Min: 9.19   Max: 56.42
Current: 12.62

9.19
56.42
ROE (%) 15.86
BMY's ROE (%) is ranked higher than
86% of the 895 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. BMY: 15.86 )
BMY' s 10-Year ROE (%) Range
Min: 13.25   Max: 78.36
Current: 15.86

13.25
78.36
ROA (%) 6.84
BMY's ROA (%) is ranked higher than
81% of the 930 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.82 vs. BMY: 6.84 )
BMY' s 10-Year ROA (%) Range
Min: 5.69   Max: 35.08
Current: 6.84

5.69
35.08
ROC (Joel Greenblatt) (%) 41.77
BMY's ROC (Joel Greenblatt) (%) is ranked higher than
94% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.02 vs. BMY: 41.77 )
BMY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 36.14   Max: 149.91
Current: 41.77

36.14
149.91
Revenue Growth (3Y)(%) -4.40
BMY's Revenue Growth (3Y)(%) is ranked higher than
55% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. BMY: -4.40 )
BMY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -4.4   Max: 11.8
Current: -4.4

-4.4
11.8
EBITDA Growth (3Y)(%) -16.30
BMY's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. BMY: -16.30 )
BMY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16.7   Max: 21.5
Current: -16.3

-16.7
21.5
EPS Growth (3Y)(%) -5.10
BMY's EPS Growth (3Y)(%) is ranked higher than
62% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. BMY: -5.10 )
BMY' s 10-Year EPS Growth (3Y)(%) Range
Min: -22.9   Max: 30.7
Current: -5.1

-22.9
30.7
» BMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

BMY Guru Trades in Q1 2014

Ronald Muhlenkamp 212,015 sh (New)
Ray Dalio 4,428 sh (New)
Jim Simons 1,491,855 sh (+3521.01%)
Steven Cohen 1,821,145 sh (+188.8%)
Vanguard Health Care Fund 29,437,761 sh (+20.35%)
Irving Kahn 29,650 sh (+7.23%)
Jeff Auxier 5,782 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
Jean-Marie Eveillard 16,520 sh (unchged)
Murray Stahl 62,672 sh (unchged)
Brian Rogers 5,864,800 sh (unchged)
Stanley Druckenmiller Sold Out
Joel Greenblatt Sold Out
George Soros Sold Out
Dodge & Cox 79,121 sh (-1%)
Bill Frels 296,839 sh (-1.3%)
Pioneer Investments 84,846 sh (-2.26%)
Mario Gabelli 686,785 sh (-6.02%)
Ken Fisher 15,733 sh (-13.26%)
Manning & Napier Advisors, Inc 206,869 sh (-14.5%)
Jeremy Grantham 4,144,419 sh (-53.64%)
Paul Tudor Jones 16,349 sh (-83.65%)
» More
Q2 2014

BMY Guru Trades in Q2 2014

Joel Greenblatt 89,363 sh (New)
Ken Fisher 49,732 sh (+216.1%)
Paul Tudor Jones 34,712 sh (+112.32%)
Jim Simons 2,459,200 sh (+64.84%)
Vanguard Health Care Fund 36,197,961 sh (+22.96%)
Brian Rogers 6,064,800 sh (+3.41%)
Pioneer Investments 85,646 sh (+0.94%)
Murray Stahl 62,972 sh (+0.48%)
Ronald Muhlenkamp 212,770 sh (+0.36%)
Steven Cohen 3,900 sh (unchged)
Ray Dalio Sold Out
Manning & Napier Advisors, Inc Sold Out
Dodge & Cox 78,921 sh (-0.25%)
Bill Frels 293,539 sh (-1.11%)
Mario Gabelli 674,685 sh (-1.76%)
Irving Kahn 27,650 sh (-6.75%)
Jean-Marie Eveillard 14,492 sh (-12.28%)
Jeff Auxier 5,043 sh (-12.78%)
Jeremy Grantham 1,821,771 sh (-56.04%)
» More
Q3 2014

BMY Guru Trades in Q3 2014

Ray Dalio 10,228 sh (New)
Dodge & Cox 90,428 sh (+14.58%)
Vanguard Health Care Fund 38,480,761 sh (+6.31%)
Mario Gabelli 700,255 sh (+3.79%)
Brian Rogers 6,264,800 sh (+3.3%)
Ken Fisher 51,201 sh (+2.95%)
Bill Frels 294,435 sh (+0.31%)
Jeff Auxier 5,043 sh (unchged)
Irving Kahn 27,650 sh (unchged)
Jean-Marie Eveillard 14,492 sh (unchged)
Pioneer Investments 84,994 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
Murray Stahl 62,942 sh (-0.05%)
Ronald Muhlenkamp 212,485 sh (-0.13%)
Jeremy Grantham 1,520,723 sh (-16.53%)
Paul Tudor Jones 14,869 sh (-57.16%)
Jim Simons 270,900 sh (-88.98%)
» More
Q4 2014

BMY Guru Trades in Q4 2014

Steven Cohen 246,400 sh (New)
Ruane Cunniff 3,670 sh (New)
Jim Simons 298,500 sh (+10.19%)
Irving Kahn 28,400 sh (+2.71%)
Vanguard Health Care Fund 39,056,361 sh (+1.5%)
Mario Gabelli 709,715 sh (+1.35%)
Dodge & Cox 91,028 sh (+0.66%)
Bill Frels 295,035 sh (+0.2%)
Jeff Auxier 5,043 sh (unchged)
Jean-Marie Eveillard 14,492 sh (unchged)
Brian Rogers 6,264,800 sh (unchged)
Ray Dalio Sold Out
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 212,290 sh (-0.09%)
Murray Stahl 62,817 sh (-0.2%)
Pioneer Investments 84,466 sh (-0.62%)
Ken Fisher 30,739 sh (-39.96%)
Jeremy Grantham 10,762 sh (-99.29%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ruane Cunniff 2014-12-31 New Buy$48.92 - $61.3 $ 62.310%3670
Ray Dalio 2014-12-31 Sold Out $48.92 - $61.3 $ 62.310%0
Ken Fisher 2014-12-31 Reduce -39.96%$48.92 - $61.3 $ 62.310%30739
Vanguard Health Care Fund 2014-09-30 Add 6.31%0.3%$47.86 - $51.96 $ 62.325%38480761
Joel Greenblatt 2014-09-30 Sold Out 0.05%$47.86 - $51.96 $ 62.325%0
Ray Dalio 2014-09-30 New Buy$47.86 - $51.96 $ 62.325%10228
Vanguard Health Care Fund 2014-06-30 Add 22.96%0.86%$46.59 - $52.19 $ 62.326%36197961
Joel Greenblatt 2014-06-30 New Buy0.05%$46.59 - $52.19 $ 62.326%89363
Ken Fisher 2014-06-30 Add 216.1%$46.59 - $52.19 $ 62.326%49732
Ray Dalio 2014-06-30 Sold Out $46.59 - $52.19 $ 62.326%0
Ronald Muhlenkamp 2014-03-31 New Buy1.9%$48.54 - $56.61 $ 62.317%212015
Vanguard Health Care Fund 2014-03-31 Add 20.35%0.73%$48.54 - $56.61 $ 62.317%29437761
George Soros 2014-03-31 Sold Out 0.05%$48.54 - $56.61 $ 62.317%0
Joel Greenblatt 2014-03-31 Sold Out 0.02%$48.54 - $56.61 $ 62.317%0
Ray Dalio 2014-03-31 New Buy$48.54 - $56.61 $ 62.317%4428
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP1000.000.20$2.00 Convertible Preferred Stock

Top Ranked Articles about Bristol-Myers Squibb Company

Vanguard Health Care Fund's Top Quarterly Holdings
Over the duration of the first quarter the Vanguard Health Care Fund purchased added three new stocks to its holdings. The fund now holds on to 86 stocks valued at $35.6 billion. The following companies are Vanguard's top portfolio holdings. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 38.40
BMY's P/E(ttm) is ranked higher than
75% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.60 vs. BMY: 38.40 )
BMY' s 10-Year P/E(ttm) Range
Min: 4.05   Max: 58.14
Current: 38.4

4.05
58.14
Forward P/E 27.17
BMY's Forward P/E is ranked higher than
84% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 58.14 vs. BMY: 27.17 )
N/A
PE(NRI) 38.50
BMY's PE(NRI) is ranked higher than
75% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.50 vs. BMY: 38.50 )
BMY' s 10-Year PE(NRI) Range
Min: 12.75   Max: 57.93
Current: 38.5

12.75
57.93
P/B 6.82
BMY's P/B is ranked higher than
59% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. BMY: 6.82 )
BMY' s 10-Year P/B Range
Min: 2.46   Max: 6.82
Current: 6.82

2.46
6.82
P/S 6.55
BMY's P/S is ranked higher than
66% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.01 vs. BMY: 6.55 )
BMY' s 10-Year P/S Range
Min: 1.63   Max: 6.47
Current: 6.55

1.63
6.47
PFCF 30.10
BMY's PFCF is ranked higher than
87% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. BMY: 30.10 )
BMY' s 10-Year PFCF Range
Min: 7.44   Max: 141.78
Current: 30.1

7.44
141.78
POCF 26.18
BMY's POCF is ranked higher than
78% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.53 vs. BMY: 26.18 )
BMY' s 10-Year POCF Range
Min: 6.95   Max: 44.77
Current: 26.18

6.95
44.77
EV-to-EBIT 37.48
BMY's EV-to-EBIT is ranked higher than
75% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.09 vs. BMY: 37.48 )
BMY' s 10-Year EV-to-EBIT Range
Min: 7   Max: 105
Current: 37.48

7
105
Shiller P/E 25.17
BMY's Shiller P/E is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 103.75 vs. BMY: 25.17 )
BMY' s 10-Year Shiller P/E Range
Min: 10.15   Max: 25.13
Current: 25.17

10.15
25.13
Current Ratio 1.75
BMY's Current Ratio is ranked higher than
63% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.36 vs. BMY: 1.75 )
BMY' s 10-Year Current Ratio Range
Min: 1.13   Max: 2.32
Current: 1.75

1.13
2.32
Quick Ratio 1.56
BMY's Quick Ratio is ranked higher than
67% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. BMY: 1.56 )
BMY' s 10-Year Quick Ratio Range
Min: 0.93   Max: 2.06
Current: 1.56

0.93
2.06
Days Inventory 124.14
BMY's Days Inventory is ranked higher than
71% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 153.90 vs. BMY: 124.14 )
BMY' s 10-Year Days Inventory Range
Min: 84.37   Max: 204.87
Current: 124.14

84.37
204.87
Days Sales Outstanding 41.90
BMY's Days Sales Outstanding is ranked higher than
88% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.97 vs. BMY: 41.90 )
BMY' s 10-Year Days Sales Outstanding Range
Min: 35.38   Max: 82.36
Current: 41.9

35.38
82.36

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.33
BMY's Dividend Yield is ranked higher than
75% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. BMY: 2.33 )
BMY' s 10-Year Dividend Yield Range
Min: 2.31   Max: 7.07
Current: 2.33

2.31
7.07
Dividend Payout 1.21
BMY's Dividend Payout is ranked higher than
81% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. BMY: 1.21 )
BMY' s 10-Year Dividend Payout Range
Min: 0.08   Max: 4
Current: 1.21

0.08
4
Dividend growth (3y) 3.00
BMY's Dividend growth (3y) is ranked higher than
77% of the 359 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. BMY: 3.00 )
BMY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 11.4
Current: 3

0
11.4
Yield on cost (5-Year) 2.76
BMY's Yield on cost (5-Year) is ranked higher than
74% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. BMY: 2.76 )
BMY' s 10-Year Yield on cost (5-Year) Range
Min: 2.65   Max: 8.12
Current: 2.76

2.65
8.12
Share Buyback Rate 1.30
BMY's Share Buyback Rate is ranked higher than
94% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.90 vs. BMY: 1.30 )
BMY' s 10-Year Share Buyback Rate Range
Min: 5.1   Max: -0.3
Current: 1.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 16.18
BMY's Price/Tangible Book is ranked higher than
56% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.29 vs. BMY: 16.18 )
BMY' s 10-Year Price/Tangible Book Range
Min: 6.33   Max: 53.3
Current: 16.18

6.33
53.3
Price/DCF (Projected) 2.09
BMY's Price/DCF (Projected) is ranked higher than
88% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.24 vs. BMY: 2.09 )
BMY' s 10-Year Price/DCF (Projected) Range
Min: 1.13   Max: 4.53
Current: 2.09

1.13
4.53
Price/Median PS Value 2.42
BMY's Price/Median PS Value is ranked higher than
58% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. BMY: 2.42 )
BMY' s 10-Year Price/Median PS Value Range
Min: 0.72   Max: 3.22
Current: 2.42

0.72
3.22
Price/Graham Number 5.21
BMY's Price/Graham Number is ranked higher than
72% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.07 vs. BMY: 5.21 )
BMY' s 10-Year Price/Graham Number Range
Min: 1.41   Max: 7.03
Current: 5.21

1.41
7.03
Earnings Yield (Greenblatt) 2.70
BMY's Earnings Yield (Greenblatt) is ranked higher than
74% of the 927 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BMY: 2.70 )
BMY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 14.3
Current: 2.7

1
14.3
Forward Rate of Return (Yacktman) -10.84
BMY's Forward Rate of Return (Yacktman) is ranked higher than
59% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.94 vs. BMY: -10.84 )
BMY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.8   Max: 26.2
Current: -10.84

-10.8
26.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:BRM.Germany, BMYMP.USA, BMYB34.Brazil, BMY.Mexico, BMY.Argentina, BMY.Switzerland,
Bristol-Myers Squibb Co, a Delaware corporation was incorporated in August 1933 under the name Bristol-Myers Company. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. It is a biopharmaceutical company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in one segment: Biopharmaceuticals. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes (typically involving recombinant DNA technology), called 'biologics'. Small molecule drugs are typically administered orally, e.g., in the form of a pill or tablet, although other drug delivery mechanisms are used as well. Biologics are typically administered to patients through injections or by infusion. Its revenues come from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience and metabolics. Regional commercial organizations are used to distribute and sell the product. The business is also supported by global corporate staff functions. These products are sold mainly to wholesalers, and to a lesser extent, directly to distributors, retailers, hospitals, clinics, government agencies and pharmacies. The Company's key products include, Plavix, Avapro, Eliquis, Reyataz, Sustiva Franchise, Baraclude, Sprycel, Yervoy, Orencia among others.The Company promotes its products directly to healthcare providers such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the U.S. through direct-to-consumer print, radio and television and digital advertising and promotion. The markets in which the Company competes are generally broad-based and highly competitive. The Company competes with other research-based drug companies, many smaller research companies and generic drug manufacturers. The Company is subject to global regulation by regional, country, state and local agencies.
» More Articles for BMY

Headlines

Articles On GuruFocus.com
Bayer Goes Into Disinvestment Mode Due To Falling Profit Numbers Feb 27 2015 
Abner Herrman's Top Three Holdings Feb 26 2015 
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 
Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
Feeling Good With This Med Company Jan 20 2015 
mom Dec 27 2014 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
A Buy Recommendation From Absolute Valuation Model to Bristol-Myers Squibb Nov 24 2014 
Blackhill Bets Almost Half of Portfolio on Williams-Sonoma Nov 10 2014 
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio Nov 09 2014 

More From Our Partners
3 Best Performing Stocks in February - Analyst Blog Mar 2 2015 - ZACKS

More From Other Websites
U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for... Mar 02 2015
How A Strong Greenback Dollar Affects the Economy Mar 02 2015
Final Glance: Pharmaceuticals companies Mar 02 2015
Bristol-Myers Squibb Announces Dividend Mar 02 2015
Midday Glance: Pharmaceuticals companies Mar 02 2015
ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After... Mar 02 2015
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Yervoy®... Mar 02 2015
[$$] Biotech Sector Addicted to M&A Drug Feb 27 2015
U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for... Feb 27 2015
U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for... Feb 27 2015
Early Glance: Pharmaceuticals companies Feb 27 2015
5 Top-Heavy Stocks to Sell: Oracle, Michael Kors and More Feb 27 2015
Bristol-Myers: Drug combo cured hepatitis C in 97% with HIV Feb 26 2015
Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in... Feb 26 2015
ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After... Feb 26 2015
Bristol hep C drug helps cure 97 pct of HIV coinfected patients-study Feb 26 2015
Rigel Pharma CEO pulls back the curtain on drug deal with Bristol-Myers Feb 26 2015
Exchange-traded funds that hold big pharma Feb 26 2015
Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in... Feb 26 2015
How to arrive at valuations for big pharma Feb 25 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK